Cargando…

Current evidence on the role of lipid lowering drugs in the treatment of psoriasis

BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiao, Zhang, Shuo, Xing, Meng, Hong, Seokgyeong, Liu, Liu, Ding, Xiao-Jie, Sun, Xiao-ying, Luo, Ying, Wang, Chun-xiao, Zhang, Miao, Li, Bin, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403729/
https://www.ncbi.nlm.nih.gov/pubmed/36035406
http://dx.doi.org/10.3389/fmed.2022.900916
_version_ 1784773443984556032
author Wang, Jiao
Zhang, Shuo
Xing, Meng
Hong, Seokgyeong
Liu, Liu
Ding, Xiao-Jie
Sun, Xiao-ying
Luo, Ying
Wang, Chun-xiao
Zhang, Miao
Li, Bin
Li, Xin
author_facet Wang, Jiao
Zhang, Shuo
Xing, Meng
Hong, Seokgyeong
Liu, Liu
Ding, Xiao-Jie
Sun, Xiao-ying
Luo, Ying
Wang, Chun-xiao
Zhang, Miao
Li, Bin
Li, Xin
author_sort Wang, Jiao
collection PubMed
description BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. RESULTS: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): −0.94; 95% CI: [−1.58, −0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: −0.92; 95% CI: [−1.39, −0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20–CCR6 interaction, and reduction in the levels of inflammatory factors. LIMITATIONS: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. CONCLUSION: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.
format Online
Article
Text
id pubmed-9403729
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94037292022-08-26 Current evidence on the role of lipid lowering drugs in the treatment of psoriasis Wang, Jiao Zhang, Shuo Xing, Meng Hong, Seokgyeong Liu, Liu Ding, Xiao-Jie Sun, Xiao-ying Luo, Ying Wang, Chun-xiao Zhang, Miao Li, Bin Li, Xin Front Med (Lausanne) Medicine BACKGROUND: Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation. OBJECTIVE: The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis. RESULTS: The study included eight randomized controlled studies, four single-arm studies, and four in vitro studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): −0.94; 95% CI: [−1.58, −0.31]; p = 0.004]. Oral statins performed best at week eight (SMD: −0.92; 95% CI: [−1.39, −0.44]; p = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20–CCR6 interaction, and reduction in the levels of inflammatory factors. LIMITATIONS: There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing. CONCLUSION: The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403729/ /pubmed/36035406 http://dx.doi.org/10.3389/fmed.2022.900916 Text en Copyright © 2022 Wang, Zhang, Xing, Hong, Liu, Ding, Sun, Luo, Wang, Zhang, Li and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wang, Jiao
Zhang, Shuo
Xing, Meng
Hong, Seokgyeong
Liu, Liu
Ding, Xiao-Jie
Sun, Xiao-ying
Luo, Ying
Wang, Chun-xiao
Zhang, Miao
Li, Bin
Li, Xin
Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title_full Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title_fullStr Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title_full_unstemmed Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title_short Current evidence on the role of lipid lowering drugs in the treatment of psoriasis
title_sort current evidence on the role of lipid lowering drugs in the treatment of psoriasis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403729/
https://www.ncbi.nlm.nih.gov/pubmed/36035406
http://dx.doi.org/10.3389/fmed.2022.900916
work_keys_str_mv AT wangjiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT zhangshuo currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT xingmeng currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT hongseokgyeong currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT liuliu currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT dingxiaojie currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT sunxiaoying currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT luoying currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT wangchunxiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT zhangmiao currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT libin currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis
AT lixin currentevidenceontheroleoflipidloweringdrugsinthetreatmentofpsoriasis